Pipeline
Otsuka Pharmaceutical collaborates actively with leading-edge academia and venture companies, in addition to using conventional drug discovery methods.
This open sharing of ideas enables us to develop unique compounds.
Psychiatry & Neurology
(Phase I, II, III, Filed / Approved)
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
<REXULTI / RXULTI>
Features: Dopamine partial agonist
Dosage form: Depot injection
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Depot injection
Origin: Otsuka Pharmaceutical
Features: Serotonin, norepinephrine and dopamine reuptake inhibitor
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Origin: Avanir
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Origin: Neurovance
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
Origin: Neurovance
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
Origin: Neurovance
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
Origin: Sunovion / PsychoGenics*
Features: TAAR1・5-HT1A agonist
Dosage form: Oral
*Sunovion discovered ulotaront (SEP-363856) in collaboration with PsychoGenics.
Origin: Sunovion / PsychoGenics*
Features: TAAR1・5-HT1A agonist
Dosage form: Oral
*Sunovion discovered ulotaront (SEP-363856) in collaboration with PsychoGenics.
Origin: Sunovion
Features: 5-HT7・D2 antagonist
Dosage form: Oral
Oncology
(Phase I, II, III, Filed / Approved)
<INQOVI>
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
<INQOVI>
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
<INQOVI>
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
Origin: Astex
Features: IAP inhibitor
Dosage form: Oral
Origin: Astex
Features: IAP inhibitor
Dosage form: Oral
decitabine, cedazuridine
Origin: Astex
Dosage form: Oral
Origin: Astex
Features: ERK1/2 inhibitor
Dosage form: Oral
Origin: Astex
Features: MDM2 inhibitor
Dosage form: Oral
Origin: Astex
Dosage form: Oral
<ICLUSIG>
Origin: Takeda Pharmaceutical
Features: BCR-ABL tyrosine kinase inhibitor
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Origin: Osaka University
Features: Activated integrin β7-targeted CAR-T cell therapy
Dosage form: Injection
Origin: Takara Bio
Features: NY-ESO-1 siTCR™ gene therapies
Dosage form: Injection
Cardiovascular & Renal areas
(Phase I, II, III, Filed / Approved)
<Samtasu>
Origin: Otsuka Pharmaceutical
Features: V2 -receptor antagonist
Dosage form: Injection
Origin: Visterra
Features: Anti-APRIL monoclonal antibody
Dosage form: Injection
Origin: Esperion
Features: ATP-citrate lyase inhibitor
Dosage form: Oral
Origin: Aurinia
Features: Calcineurin inhibitor
Dosage form: Oral
Other therapeutic areas
(Phase I, II, III, Filed / Approved)
<Deltyba>
Features: Mycolic acid biosynthesis inhibitor
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Features: DPrE1 inhibitor
Dosage form: Oral
(Phase I, II, III, Filed / Approved)
<Samtasu>
Origin: Otsuka Pharmaceutical
Features: V2 -receptor antagonist
Dosage form: Injection
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Depot injection
Origin: Aurinia
Features: Calcineurin inhibitor
Dosage form: Oral
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
Origin: Avanir
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Origin: Neurovance
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
Origin: Sunovion / PsychoGenics*
Features: TAAR1・5-HT1A agonist
Dosage form: Oral
*Sunovion discovered ulotaront (SEP-363856) in collaboration with PsychoGenics.
Origin: Sunovion
Features: 5-HT7・D2 antagonist
Dosage form: Oral
<INQOVI>
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
<Deltyba>
Features: Mycolic acid biosynthesis inhibitor
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Origin: Neurovance
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
Origin: Sunovion / PsychoGenics*
Features: TAAR1・5-HT1A agonist
Dosage form: Oral
*Sunovion discovered ulotaront (SEP-363856) in collaboration with PsychoGenics.
Origin: Otsuka Pharmaceutical
Features: Serotonin, norepinephrine and dopamine reuptake inhibitor
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Origin: Neurovance
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
<INQOVI>
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
Origin: Astex
Features: IAP inhibitor
Dosage form: Oral
<ICLUSIG>
Origin: Takeda Pharmaceutical
Features: BCR-ABL tyrosine kinase inhibitor
Dosage form: Oral
Origin: Visterra
Features: Anti-APRIL monoclonal antibody
Dosage form: Injection
Origin: Esperion
Features: ATP-citrate lyase inhibitor
Dosage form: Oral
Origin: Astex
Features: ERK1/2 inhibitor
Dosage form: Oral
Origin: Astex
Features: MDM2 inhibitor
Dosage form: Oral
Origin: Osaka University
Features: Activated integrin β7-targeted CAR-T cell therapy
Dosage form: Injection
Origin: Takara Bio
Features: NY-ESO-1 siTCR™ gene therapies
Dosage form: Injection
Origin: Otsuka Pharmaceutical
Features: DPrE1 inhibitor
Dosage form: Oral
<REXULTI / RXULTI>
Features: Dopamine partial agonist
Dosage form: Depot injection
Origin: Otsuka Pharmaceutical
Dosage form: Oral
<INQOVI>
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
Origin: Astex
Features: IAP inhibitor
Dosage form: Oral
decitabine, cedazuridine
Origin: Astex
Dosage form: Oral
Origin: Astex
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Dosage form: Oral
- Note: In general, Otsuka discloses clinical trial projects that are in Phase II or later stage of development, however, only clinical trial projects in Phase I conducted with patients are disclosed.
(as of March 31, 2022)